

Filed Electronically February 6, 2007

<b>REQUEST FOR CORRECTED FILING RECEIPT</b>  Address to: Mail Stop <b>OIPE</b> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	AREN-017 (17.US3.REG)
	Applicant	LEHMANN-BRUINSMA, KARIN
	Serial Number	09/826,509
	Filing Date	April 5, 2001
	Group Art Unit	1646
	Examiner Name	LI, RUIXIANG
	Title:	<i>"NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED KNOWN G PROTEIN-COUPLED RECEPTORS"</i>

Sir:

A filing receipt for the above-identified patent application has been issued by the U.S. Patent and Trademark Office (copy attached).

**Please correct the Atty Docket No. to read: AREN-017 (17.US3.REG)** as indicated on the marked-up filing receipt attached herewith.

If for any reason a fee is found to be necessary, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0815.

Respectfully submitted,

BOZICEVIC, FIELD &amp; FRANCIS LLP

Date: February 6, 2007By: Carol L. Francis, Ph.D.  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/826,509	04/05/2001	1646	1093	AREN-0207	7	102	1

AREN-017(17. US3. REF)

CONFIRMATION NO. 7872

## CORRECTED FILING RECEIPT



\*OC000000007262881\*

Gwilym J. O. Attwell  
Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103

RECEIVED

JAN 9 2002

Date Mailed: 01/03/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Karin Lehmann-Bruinsma, San Diego, CA;  
Chen W. Liaw, San Diego, CA;  
I-Lin Lin, San Diego, CA;

RECEIVED

JAN 9 2002

DOCKET DEPT.  
WWKMN

## Assignment For Published Patent Application

Arena Pharmaceuticals, Inc.;

## Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/195,747 04/07/2000

## Foreign Applications

If Required, Foreign Filing License Granted 05/30/2001

Projected Publication Date: 11/29/2001

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Non-endogenous, constitutively activated known G protein-coupled receptors

**Preliminary Class**

536

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).